Related Experiment Video
Updated: Jun 24, 2026
10:18
From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
Published on: October 19, 2014
13.7K
Primary diffuse large B-cell lymphoma of bone in adults: A SEER population-based study
Jing Li1, Xiangpeng Li, Tong Gao
1Department of Clinical Pharmacy, Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.
Medicine
|October 29, 2024
Summary
This study defines clinical features and survival for primary bone diffuse large B-cell lymphoma (PB-DLBCL). Developed nomograms accurately predict patient survival, aiding treatment optimization for this rare lymphoma.
Area of Science:
- Hematology
- Oncology
- Epidemiology
Background:
- Primary diffuse large B-cell lymphoma of the bone (PB-DLBCL) is a rare extranodal lymphoma with poorly defined clinical characteristics and outcomes.
- Understanding prognostic factors and survival is crucial for managing adult PB-DLBCL patients.
Purpose of the Study:
- To investigate the clinical manifestations, staging, therapeutic options, prognostic factors, and survival outcomes of adult PB-DLBCL.
- To develop predictive models (nomograms) for survival outcomes in PB-DLBCL patients.
Main Methods:
- Utilized data from the Surveillance, Epidemiology, and End Results (SEER) Program (2000-2018) for adult PB-DLBCL patients.
- Employed Kaplan-Meier analysis for survival rates and Cox regression (including BESS and LASSO) for nomogram construction.
- Validated nomograms using concordance index, calibration curves, and decision curve analysis (DCA).
Main Results:
- Diffuse large B-cell lymphoma (DLBCL) constituted 67.51% of primary bone lymphomas, commonly affecting the spine and lower limbs.
- Overall survival (OS) rates at 3, 5, 10, and 15 years were 74.9%, 70.5%, 60.0%, and 49.9%, respectively.
- Nomograms for OS and disease-specific survival (DSS) identified key predictors including age, Ann Arbor stage, primary site, therapy, marital status, number of bone lesions, and year of diagnosis.
Conclusions:
- Nomograms developed for PB-DLBCL demonstrate good accuracy and clinical utility in predicting patient survival.
- These predictive models can assist clinicians in optimizing treatment strategies for adult patients with PB-DLBCL.
- Further research can refine understanding and management of this rare hematologic malignancy.
Related Concept Videos
02:21Cancers Originate from Somatic Mutations in a Single Cell
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
02:21Cancers Originate from Somatic Mutations in a Single Cell
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...